Overcoming MCL-1-driven adaptive resistance to targeted therapies
Two complementary studies in Nature Communications define a critical role for the anti-apoptotic protein MCL-1 as a driver of adaptive survival in tumor cells treated with oncogene targeted therapies, providing a rationale for combining these agents with newly developed MCL-1 inhibitors in the clini...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2020-01-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-020-14392-z |